

Budget Update

**NIH Director's Report to the Advisory
Committee to the Director
December 9, 2021**

**Neil K. Shapiro
Associate Director for Budget, NIH**



FY 2022 So Far

- Currently under a Continuing Resolution
 - First through December 3, 2021.
 - Second through February 18, 2022.
 - Funding level is FY 2021 enacted, prorated for the time period.
- Type 1 Diabetes mandatory funding is already appropriated, but reduced by 5.7 percent (from \$150 to \$141.45 million) due to sequestration.
- Discretionary spending caps and the associated sequestration expired in FY 2021.

Appropriations Action

- House LHHS bill approved by Subcommittee on July 12 and full Committee on July 15.
- Passed by the House on July 29 in a “minibus” with six other bills.
- On October 18, the Senate Appropriations Committee released bill language and an explanatory statement for LHHS and eight other bills that had not been approved by the Committee.
- Both House (+\$6.7B) and Senate (+\$5.2B) levels would be major increases to the NIH budget.

FY 2022 Comparison

\$ in billions	FY 2021 Enacted	FY 2022 PB	FY 2022 House	FY 2022 Senate
Program Level	42.94	51.96	49.66	48.15
+/- FY 2021		+9.02	+6.72	+5.21
<i>ARPA-H</i>		6.50	3.00	2.40
<i>Other Increases</i>		2.52	3.72	2.81

- Both the House and Senate supported funding for the Advanced Research Projects Agency for Health (ARPA-H), contingent on authorizing legislation.

FY 2022 Targeted Increases

\$ in millions	FY 2022 PB	FY 2022 House	FY 2022 Senate
Opioids/pain (inc. HEAL)	627	627	616
Health disparities	330	330	330
Alzheimer's disease	--	200	235
Cybersecurity	100	100	100
Climate change	100	100	100
COVID-19	70	95	77.5
Buildings & Facilities	50	50	75

- NIH research priorities in the President's Budget received strong support in both House and Senate.

COVID-19 Emergency Supplementals

- NIH continues critical COVID-19 research begun in FY 2020 and FY 2021, using supplemental appropriations to NIH as well as amounts from the Public Health and Social Services Emergency Fund under delegated authority from HHS.
- The \$3.2 billion Antiviral Program for Pandemics, supported under the American Rescue Plan Act, will accelerate the discovery, development and manufacturing of antiviral medicines for COVID-19 while building sustainable platforms to address other viruses with pandemic potential.